BACKGROUND AND OBJECTIVE: Concerns that antiepileptic brand-to-generic interchange results in disruption of @entity410 control are widespread. The objective of this study was to evaluate the safety and tolerability of the brand-to-generic @entity4677 switch in @entity1 with focal or generalized @entity302 . METHODS: A prospective study in @entity1 with primary, cryptogenic or symptomatic @entity302 , who were taking branded @entity4677 and were switched to generic @entity4677 . @entity1 were consecutively recruited from January 2013 to January 2015. We evaluated efficacy, tolerability and compliance before switching (T0) and after 6  months of therapy (T1). Evaluations were scheduled as follows: baseline, 7 and 15  days, 1, 3 and 6  months. At each visit clinical diary @entity410 , physical and neurological examination, laboratory parameters and electroencephalogram were evaluated. RESULTS: Fifty-nine @entity1 , equally mixed by sex, were included in the study. Mean age was 26.1  years. Forty-seven per cent of the @entity1 enrolled received @entity4677 as monotherapy. One @entity1 was lost during the follow-up: so at T1 we had 58 @entity1 (28 monotherapy and 30 polytherapy). At T0 and at T1, there was no statistically significant difference in terms of @entity410 frequency and intensity, occurrence of adverse events, laboratory parameters and electroencephalographic features. Two @entity1 stopped treatment with the generic (both at 3  months after the switch) and restarted therapy with brand @entity4677 because of @entity410 increase. At the end of the study, the switchback rate was 3.4  %. CONCLUSIONS: No increase of @entity410 and adverse effects were observed when branded @entity4677 was interchanged to a generic equivalent. More studies should be conducted with a larger series of @entity1 to confirm these results.

Safety of Overnight Switch from Brand-Name to Generic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity4677 :: ('MESH:C026098', 'Chemical') :: ['levetiracetam'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']
@entity4677 :: (MESH:C026098,Chemical) :: ['Levetiracetam']
